Mallinckrodt to Buy Closely Held Therakos for $1.33 Billion

Mallinckrodt Plc agreed to buy closely held immunotherapy company Therakos Inc. from investment firm Gores Group LLC in a transaction valued at $1.33 billion.

The transaction will add at least 10 U.S. cents a share to its adjusted fiscal 2016 earnings, and more in the following years, St. Louis, Missouri-based Mallinckrodt said in a statement on Monday. The companies expect to complete the transaction in the third quarter.